.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have discovered that IL-39 in Myasthenia Gravis (MG) serves as a potent indicator of disease severity. This novel cytokine, a member of the IL-12 family, appears to play a critical role in the immune-mediated pathology of the condition.
Moreover, a study conducted by Jia K and colleagues analyzed serum samples from 51 patients with acetylcholine receptor (AChR) antibody-positive MG. They compared these to 43 healthy controls to establish a baseline for comparison. The results showed that active MG patients had significantly higher IL-39 levels than healthy individuals.
Furthermore, the study found a strong positive correlation between IL-39 concentrations and clinical assessment tools like the MG-ADL score. Patients with more severe symptoms, categorized under higher MGFA classifications, consistently displayed elevated cytokine levels. Significantly, when patients achieved remission after immunotherapy, their IL-39 levels dropped sharply.
Consequently, this suggests that the cytokine could act as a longitudinal biomarker to monitor treatment efficacy in clinical settings. Overall, IL-39 offers high diagnostic accuracy, as shown by an area under the curve (AUC) of 0.922. Doctors may soon use this measurement to improve personalized care for MG patients.
IL-39 levels correlate with disease activity scores. Doctors can use these measurements to determine the severity of the condition and monitor how well a patient responds to immunotherapy.
Yes, research shows that patients with active MG have significantly higher serum IL-39 levels compared to healthy controls, with a high diagnostic accuracy rate.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Serum IL-39 shows promise as a new biomarker for Myasthenia Gravis, helping clinicians track disease activity and monitor response to immunotherapy....
6 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
